Case Report
Volume: 6 | Issue: 6 | Published: Oct 10, 2022 | Pages: 95 - 101 | DOI: 10.24911/ejmcr/173-1642670323
Concomitant multiple sclerosis and ankylosing spondylitis: a clinical case report
Authors: Zeltina Estere , Meksa Liga , Kadisa Anda , Karelis Guntis , Pastare Daina , Svilpe Sandra , Polunosika Elina , Jaunozolina Liga
Article Info
Authors
Zeltina Estere
Faculty of Medicine and Healthcare, Riga Stradins University, Latvia
Meksa Liga
Neurology and Neurosurgery Department, Riga East Univesity Hospital clinic "Gaiļezers", Latvia
Kadisa Anda
Faculty of Medicine and Healthcare, Riga Stradins University, Latvia, Internal Diseases Department, Riga East Univesity Hospital clinic "Gaiļezers", Latvia
Karelis Guntis
Faculty of Medicine and Healthcare, Riga Stradins University, Latvia, Neurology and Neurosurgery Department, Riga East Univesity Hospital clinic "Gaiļezers", Latvia
Pastare Daina
Faculty of Medicine and Healthcare, Riga Stradins University, Latvia, Neurology and Neurosurgery Department, Riga East Univesity Hospital clinic "Gaiļezers", Latvia
Svilpe Sandra
Neurology and Neurosurgery Department, Riga East Univesity Hospital clinic "Gaiļezers", Latvia
Polunosika Elina
Faculty of Medicine and Healthcare, Riga Stradins University, Latvia, Neurology and Neurosurgery Department, Riga East Univesity Hospital clinic "Gaiļezers", Latvia
Jaunozolina Liga
Radiology Department, Riga East Univesity Hospital clinic "Gaiļezers", Latvia.
Publication History
Received: January 23, 2022
Accepted:
Published: October 10, 2022
Abstract
Background: The therapy of patients with concomitant multiple sclerosis (MS) and ankylosing spondylitis (AS) is a challenge for clinicians. Secukinumab is effective in the treatment of MS. In the clinical case, we present, substantial clinical and radiological remission in the case of both autoimmune diseases was observed. Case Presentation: A male adult was diagnosed with relapsing-remitting MS. The patient complained of severe thoraco-lumbar pain. Magnetic resonance imaging (MRI) led to a diagnosis of AS. Considering that nonsteroidal anti-inflammatory drugs were ineffective and tumor necrosis factor-α blockers are contraindicated in patients with MS, secukinumab was prescribed. MRI 8 months after initiation of therapy provided clinical stability in consideration of the two autoimmune comorbidities. Conclusion: Secukinumab is an effective therapy for concomitant MS and AS.
Keywords: Multiple sclerosis, ankylosing spondylitis, secukinumab, autoimmune disease, case report, green
